The tire curing bladder release agent market is poised for remarkable growth over the next decade, forecast to climb from USD ...
The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...
Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...
Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback